Delivers patient satisfaction*¹ and improved engagement¹ by allowing patients to do physical therapy at home, on demand and without using wearable sensors
LONDON, May 5, 2021 /PRNewswire/ — Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces the launch of ARIA Home PT, a remote physical therapy product as part of the ARIA suite of solutions.
ARIA Home PT offers a customized experience for patients on their time and in their home, while still providing relevant actionable data for clinicians, by leveraging advanced technology, telehealth solutions from licensed physical therapists (PTs) and digital avatar-based guidance. This allows orthopaedic surgeons and PTs responsible for the entire outpatient total joint replacement episode of care help drive better outcomes.
ARIA Home PT utilizes an interactive experience to deliver measurable improvements in patient adherence and cost reduction – an innovative approach shown to be as safe and effective as traditional physical therapy in a randomized control trial. ARIA Home PT reported decreased readmissions (60%), outpatient visits (86%), home health visits (95%), and urgent care or ER visits (30%), helping save an average of $2,745 per patient.1
ARIA Home PT features advanced technology that keeps patients actively engaged in their own care and recovery, and care teams fully informed of each patient’s progress. Utilizing a 3D motion tracking technology-based solution for use at a patient’s home, it educates, engages and guides the patient through their PT regimen and provides robust data for clinician and PT review including number, duration and quality of reps on twenty-five different joints. It further provides the built-in ability for tele-consultation between patients and their clinicians. As a result, ARIA Home PT has been shown to improve patient adherence by 35%1, and patients love it, with a Net Promoter Score of 90.3 (above 70 is considered world class.)2 Additionally, an aging population means greater demand for PT amid a forecast for an estimated shortage in licensed therapists by 2025 based on an attrition rate of >2.5%.3
“The launch of ARIA Home PT reinforces our commitment to help patients live a life unlimited via a full suite of products for the entire clinical episode of care,” said Laura Rector, Vice President for Ambulatory Surgery Centers and Digital Health at Smith+Nephew. “Now more than ever, remote telehealth solutions are critical to the success of our customers and the care of their patients.”
To learn more about ARIA Home PT, or to request a product demonstration, visit www.think-aria.com.
*As compared to traditional PT
- Bettger JP, Green CL, Holmes DN, et al. Effects of Virtual Exercise Rehabilitation In-home Therapy Compared with Traditional Care After Total Knee Arthroplasty: VERITAS, a randomized controlled trial. J Bone Joint Surg Am. 2020;102:101-9.
- Kuether J, Moore A, Kahan J, et al. Telerehabilitation for total hip and knee arthroplasty patients: a pilot series with high patient satisfaction. HSS J. 2019;15:221–225.
- American Physical Therapy Association. A Model to Project the Supply and Demand of Physical Therapists 2010-2025. 2017 (April 17).
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc
Be the first to comment